
Verena Peters

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4621258/publications.pdf Version: 2024-02-01



VEDENA DETEDS

#	Article	IF	CITATIONS
1	Carnosine as a Protective Factor in Diabetic Nephropathy. Diabetes, 2005, 54, 2320-2327.	0.6	264
2	Carnosine enhances diabetic wound healing in the db/db mouse model of type 2 diabetes. Amino Acids, 2012, 43, 127-134.	2.7	70
3	Protective Actions of Anserine Under Diabetic Conditions. International Journal of Molecular Sciences, 2018, 19, 2751.	4.1	57
4	Intrinsic carnosine metabolism in the human kidney. Amino Acids, 2015, 47, 2541-2550.	2.7	55
5	Carnosine treatment largely prevents alterations of renal carnosine metabolism in diabetic mice. Amino Acids, 2012, 42, 2411-2416.	2.7	52
6	Quo vadis: the reâ€definition of "inborn metabolic diseases― Journal of Inherited Metabolic Disease, 2015, 38, 1003-1006.	3.6	48
7	Anserine inhibits carnosine degradation but in human serum carnosinase (CN1) is not correlated with histidine dipeptide concentration. Clinica Chimica Acta, 2011, 412, 263-267.	1.1	47
8	Methylglyoxal and Advanced Glycation End Products in Patients with Diabetes – What We Know so Far and the Missing Links. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, 497-504.	1.2	39
9	Hydrogen Sulfide and Carnosine: Modulation of Oxidative Stress and Inflammation in Kidney and Brain Axis. Antioxidants, 2020, 9, 1303.	5.1	37
10	Biochemical characterization of human 3-methylglutaconyl-CoA hydratase and its role in leucine metabolism. FEBS Journal, 2006, 273, 2012-2022.	4.7	36
11	Relevance of allosteric conformations and homocarnosine concentration on carnosinase activity. Amino Acids, 2010, 38, 1607-1615.	2.7	36
12	<i>N</i> -Glycosylation of Carnosinase Influences Protein Secretion and Enzyme Activity. Diabetes, 2010, 59, 1984-1990.	0.6	35
13	Carnosinase, diabetes mellitus and the potential relevance of carnosinase deficiency. Journal of Inherited Metabolic Disease, 2018, 41, 39-47.	3.6	32
14	A scavenger peptide prevents methylglyoxal induced pain in mice. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 654-662.	3.8	30
15	Identification and characterisation of carnostatine (SAN9812), a potent and selective carnosinase (CN1) inhibitor with in vivo activity. Amino Acids, 2019, 51, 7-16.	2.7	29
16	Carnosine metabolism in diabetes is altered by reactive metabolites. Amino Acids, 2015, 47, 2367-2376.	2.7	28
17	Carnosine decreases IGFBP1 production in db/db mice through suppression of HIF-1. Journal of Endocrinology, 2015, 225, 159-167.	2.6	28
18	Carnosine and Diabetic Nephropathy. Current Medicinal Chemistry, 2020, 27, 1801-1812.	2.4	27

VERENA PETERS

#	Article	IF	CITATIONS
19	Does low serum carnosinase activity favor high-intensity exercise capacity?. Journal of Applied Physiology, 2014, 116, 553-559.	2.5	23
20	Carnosine Catalyzes the Formation of the Oligo/Polymeric Products of Methylglyoxal. Cellular Physiology and Biochemistry, 2018, 46, 713-726.	1.6	22
21	Carnosine Activates Cellular Stress Response in Podocytes and Reduces Glycative and Lipoperoxidative Stress. Biomedicines, 2020, 8, 177.	3.2	22
22	Different conformational forms of serum carnosinase detected by a newly developed sandwich ELISA for the measurements of carnosinase concentrations. Amino Acids, 2012, 43, 143-151.	2.7	20
23	Allosteric inhibition of carnosinase (CN1) by inducing a conformational shift. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 1102-1110.	5.2	20
24	CNDP1 knockout in zebrafish alters the amino acid metabolism, restrains weight gain, but does not protect from diabetic complications. Cellular and Molecular Life Sciences, 2019, 76, 4551-4568.	5.4	14
25	Peer review fraud—it's not big and it's not clever. Journal of Inherited Metabolic Disease, 2016, 39, 1-2.	3.6	12
26	The <i>CNDP1</i> (CTG) ₅ Polymorphism Is Associated with Biopsy-Proven Diabetic Nephropathy, Time on Hemodialysis, and Diabetes Duration. Journal of Diabetes Research, 2017, 2017, 1-11.	2.3	12
27	Novel variants and clinical symptoms in four new ALG3â€CDG patients, review of the literature, and identification of AAGRPâ€ALG3 as a novel ALG3 variant with alanine and glycineâ€rich Nâ€terminus. Human Mutation, 2019, 40, 938-951.	2.5	12
28	A Global Cndp1-Knock-Out Selectively Increases Renal Carnosine and Anserine Concentrations in an Age- and Gender-Specific Manner in Mice. International Journal of Molecular Sciences, 2020, 21, 4887.	4.1	11
29	CNDP1 genotype and renal survival in pediatric nephropathies. Journal of Pediatric Endocrinology and Metabolism, 2016, 29, 827-33.	0.9	10
30	Allelic variation in the CNDP1 gene and its lack of association with longevity and coronary heart disease. Mechanisms of Ageing and Development, 2006, 127, 817-820.	4.6	9
31	Formation of 3-hydroxyglutaric acid in glutaric aciduria type I: in vitro participation of medium chain acyl-CoA dehydrogenase. JIMD Reports, 2019, 47, 30-34.	1.5	8
32	Carnosinase concentration, activity, and CNDP1 genotype in patients with type 2 diabetes with and without nephropathy. Amino Acids, 2019, 51, 611-617.	2.7	8
33	A Novel UPLC-MS/MS Method Identifies Organ-Specific Dipeptide Profiles. International Journal of Molecular Sciences, 2021, 22, 9979.	4.1	7
34	Qualitative urinary organic acid analysis: 10 years of quality assurance. Journal of Inherited Metabolic Disease, 2016, 39, 683-687.	3.6	6
35	Newborn screening: To <scp>WES</scp> or not to <scp>WES</scp> , that is the question. Journal of Inherited Metabolic Disease, 2020, 43, 904-905.	3.6	6
36	Fatal outcome after heart surgery in PMM2-CDG due to a rare homozygous gene variant with double effects. Molecular Genetics and Metabolism Reports, 2020, 25, 100673.	1.1	5

VERENA PETERS

#	Article	IF	CITATIONS
37	Clinical Trials on Diabetic Nephropathy: A Cross-Sectional Analysis. Diabetes Therapy, 2019, 10, 229-243.	2.5	3
38	Do inborn errors of metabolism confer or impede the risk of diabetes?. Journal of Inherited Metabolic Disease, 2018, 41, 1-2.	3.6	2
39	Recommendations and guidelines in the JIMD: suggested procedures and avoidance of conflicts of interest. Journal of Inherited Metabolic Disease, 2016, 39, 327-329.	3.6	1
40	Quo vadis now: Beyond genomics to an era of personalised medicine. Journal of Inherited Metabolic Disease, 2022, 45, 129-131.	3.6	0
41	MO465: Molecular Mechanisms of Vascular Ageing in Children With Chronic Kidney Disease. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0